Fig. 1

Values and concerns associated with high-priced potential cures. Note Level of agreement on the above factors was surveyed using a five-point likert scale (1 = strongly disagree, 5 = strongly agree), following focus group interviews to quantitatively summarise the stakeholders’ perspectives in a consistent manner. Values were presented as either percentages or mean (M) with standard deviation (SD), as indicated. Non-pharma includes policy & clinical experts, government payers, civic groups, and patient groups. Abbreviations P&R, pricing and reimbursement